Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin

Despite improvements in treatment regimens for osteosarcoma (OS) patients, survival rate has not increased over the last two decades. New treatment modalities are therefore warranted. Preclinical results with conditionally replicative adenoviruses (CRAds) to treat OS are promising. One type of CRAd...

Descripción completa

Detalles Bibliográficos
Autores principales: Graat, H C A, Witlox, M A, Schagen, F H E, Kaspers, G J L, Helder, M N, Bras, J, Schaap, G R, Gerritsen, W R, Wuisman, P I J M, van Beusechem, V W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361338/
https://www.ncbi.nlm.nih.gov/pubmed/16736005
http://dx.doi.org/10.1038/sj.bjc.6603189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361338/
https://www.ncbi.nlm.nih.gov/pubmed/16736005
http://dx.doi.org/10.1038/sj.bjc.6603189

Ejemplares similares